Chemora

Chemora AI Research

Developing next generation immuno-oncology and targeted therapies through strategic global in-licensing and AI Clinical Development platform.

Assets:

  • 1 Integrin beta-6 (IB6)
  • 2 PD-L1 x VEGF bispecific
  • 3 Next generation CTLA-4

Bispecific Antibodies: Engineered proteins that simultaneously bind to a cancer cell and an immune T-cell, forcing them together.

Immunotherapy: Works by training the immune system to do more to fight cancer.